BiotechTube
QuiaPEG Pharmaceuticals

QuiaPEG Pharmaceuticals

QUIA
Uppsala, Sweden· Est.
quiapeg.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Quia Pharma AB, founded in 2008, is a Nasdaq First North-listed company that has undergone a radical strategic shift. Originally developing PEGylation technologies for drug delivery, it now operates a direct-to-consumer supplement business and is developing a transdermal GLP-1 patch for obesity. The company is in a state of significant distress, with its market maker agreement terminated and a clear intention to delist from the public market, casting severe doubt on its viability and strategic execution.

ObesityGeneral Health

Technology Platform

Historical expertise in PEGylation for drug delivery; currently developing a transdermal patch technology for the delivery of GLP-1 receptor agonists.

Opportunities

The global obesity therapeutics market is enormous and growing.
A convenient, needle-free transdermal patch for a GLP-1 agonist could theoretically address adherence issues and capture a niche segment, if the profound technical and commercial challenges can be overcome.

Risk Factors

Extreme financial distress and intent to delist signal imminent collapse.
The GLP-1 patch program is a high-risk, unfunded moonshot in a field dominated by well-capitalized pharmaceutical giants.
The consumer supplement business is undifferentiated and operates in a low-margin, hyper-competitive market.

Competitive Landscape

For its GLP-1 patch, Quia faces insurmountable competition from Novo Nordisk and Eli Lilly, who own the market and are advancing next-generation therapies. In supplements, it competes with thousands of DTC brands and large consumer health companies without any discernible competitive advantage.

More companies in Sweden →